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Abstract The objective was to compare the pharmacody-
namic (PD) and pharmacokinetic (PK) effects of ticagrelor
with clopidogrel among subjects of Hispanic ethnicity, as the
PD and PK effects of antiplatelet agents among Hispanics are
not specifically known. This was a randomised, open-label,
crossover PD/PK study of 40 Hispanic subjects with stable
coronary artery disease (CAD). Subjects were allocated to
either ticagrelor 180 mg loading dose (LD)/90 mg twice-
daily maintenance dose (MD) followed by clopidogrel
600 mg LD/75 mg once-daily MD with an intervening
washout period, or vice versa. The primary endpoint was on-
treatment reactivity (OTR) at 2 h post-LD according to the
VerifyNow P2Y12 test. OTR was significantly lower at 2 h
post-LD with ticagrelor compared with clopidogrel (34 PRU
vs. 201 PRU, least square means difference = -167 PRU
[95 % CI, -197, -137], P \ 0.001). OTR was also lower
with ticagrelor at 30 min and 8 h post-LD (P \ 0.001). The
greater magnitude of antiplatelet effect with ticagrelor per-
sisted after 7 days of MD (52 PRU [95 % CI, 30, 73] vs. 182
PRU [95 % CI, 160, 205], P \ 0.001). Mean plasma con-
centration of ticagrelor and its active metabolite were
greatest at 2 h post-LD, with similar levels at 2 h post-MD
after 7 days of MD. Among Hispanic subjects with stable
CAD, ticagrelor provides a more rapid onset of platelet
inhibition and a significantly greater antiplatelet effect
compared with clopidogrel during both the loading and
maintenance phases of treatment.
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Introduction
Coronary artery disease (CAD) and acute coronary syndrome
(ACS) are leading causes of mortality in the United States [1].
Interventions that may reduce the incidence of ACS or miti-
gate its sequelae are therefore of substantial societal benefit.
However, the populations evaluated in most randomised
cardiovascular outcomes trials do not reflect the broad range
of ethnicities to which the therapies studied may be subse-
quently applied in clinical practice. Engaging under-repre-
sented communities in research and identifying patient
subgroups whose response to a given therapy may differ from
that of the average patient in a trial are priorities for scientific
research and investment [2]. Hispanics in the United States
have higher rates of diabetes mellitus, metabolic syndrome
and obesity than non-Hispanic whites, have a substantial
burden of cardiovascular disease, and are a growing fraction of
the national population. Ticagrelor is an oral platelet P2Y12-
receptor antagonist that significantly reduces major cardio-
vascular events after ACS compared with clopidogrel, driven
by reductions in myocardial infarction and cardiovascular
death, without a significant increase in all-cause major
bleeding, although non-coronary artery bypass grafting rela-
ted bleeding is increased [3]. We sought to evaluate the anti-
platelet effects of ticagrelor compared with clopidogrel in
Hispanic subjects with established CAD.
Materials and methods
Study design
This was a randomised, open-label, crossover study con-
ducted at six sites within the United States (See Online
Appendix for study sites). The study was approved by the
Institutional Review Boards at all sites and was conducted
in accord with the provisions of the Declaration of Hel-
sinki. All subjects provided written, informed consent
(clinicaltrials.gov identifier, NCT01523366).
Study population
Subjects were eligible to be enrolled if they were a His-
panic male or female C18 years of age, were receiving
aspirin 75–100 mg daily maintenance dose (MD), and had
documented stable CAD according to one of the following
criteria: (a) current or history of stable angina with objec-
tive evidence of CAD; (b) prior myocardial infarction; or
(c) prior surgical or percutaneous coronary revascularisa-
tion. Hispanic ethnicity was based upon self-identification.
Major exclusion criteria included any indication for oral
anticoagulation or dual antiplatelet therapy, and concomi-
tant therapy with strong CYP3A4 inhibitors or inducers.
Detailed inclusion and exclusion criteria and participating
sites are listed in the Online Appendix.
Study procedures
Subjects were randomised 1:1 to receive one of two possible
treatment sequences: either open-label clopidogrel in the
first period followed by open-label ticagrelor in the second
period or vice versa (Fig. 1). There was a 10–14 days
washout between periods. Clopidogrel was administered as a
600 mg loading dose (LD) followed by a 75 mg once-daily
MD for 7–9 days, and ticagrelor was administered as a
180 mg LD followed by a 90 mg twice-daily MD for
7–9 days. Subjects received aspirin 75–100 mg once-daily,
which was maintained at a constant dose throughout the
study. To evaluate the onset of anti-platelet effect, platelet
reactivity was assessed at baseline prior to the LD and at 0.5,
2 and 8 h after the LD; to evaluate the effect of the MD,
platelet reactivity was assessed just prior to, 2, and 8 h after
the last morning dose, and 12 h after the last evening dose of
ticagrelor and 24 h after the last morning dose of clopidogrel.
Blood samples to analyse the plasma concentrations of ti-
cagrelor and its active metabolite, AR-C124910XX, were
drawn at the same time as platelet reactivity assessment.
Platelet reactivity measurement
Platelet reactivity was assessed using the VerifyNow
P2Y12 test, which measures adenosine diphosphate-
induced platelet aggregation as an increase in light trans-
mittance and reports values in P2Y12 reaction units (PRU).
A higher PRU reflects greater platelet reactivity [4].
Although study treatment was open-label, the PRU results
were blinded to study personnel.
Definitions and endpoints
The primary endpoint was the inhibition of the platelet
P2Y12 receptor at 2 h after the LD, as measured by least
squares (LS) means difference in PRU. Secondary end-
points included the PRU at 0.5 and 8 h after the LD; the
PRU at 2, 8 h, and the end-of-dosing interval of the MD
(12 h after last evening dose for ticagrelor or 24 h after last
dose of clopidogrel); and the percent reduction of PRU
from baseline at the time-points measured, i.e. (1 - [PRU
after study drug/PRU at baseline]) 9 100.
Statistical analysis
Categorical variables are reported as counts and percent-
ages, and continuous variables as mean ± standard devia-
tion (SD). The primary analysis of the difference in PRU
between ticagrelor and clopidogrel at 2 h after the LD was
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performed using a mixed-effect model with fixed effects
for period, treatment sequence, treatment, and a random
effect for patient within sequence. Mean on-treatment
reactivity was estimated using LS means and two-sided
95 % confidence intervals (CIs). Distribution assumptions
underlying the analysis were assessed by residual plots.
Secondary analyses of on-treatment reactivity at other
timepoints were performed with similar mixed effects
models. Several sensitivity analyses were performed. In
one pre-specified analysis, platelet reactivity at baseline
was included as a fixed effect. In addition, a post hoc
analysis was performed including treatment periods in
which the baseline on-treatment reactivity prior to study
drug administration was \150 PRU, which was thought to
be due to incomplete washout of study drug.
A sample size of 12 subjects was required to provide
90 % power to detect a difference in on-treatment reac-
tivity of 100 PRU between ticagrelor and clopidogrel at
2 h post-LD, assuming a SD of 93 PRU, a correlation of
0.5 between paired observations, and a two-sided alpha
level of 0.05. Based on a need to enrol a cohort of sufficient
size for clinical credibility and to evaluate P2Y12 receptor
inhibition at secondary timepoints and to collect potential
adverse events, it was planned that 34 subjects would be
enrolled in order to ensure 28 subjects were evaluable. This
would provide more than 99 % power to detect the antic-
ipated primary outcome effect.
Results
Study flow is shown in Fig. 2. A total of 40 subjects were
randomised. All subjects received at least one dose of ti-
cagrelor and 39 subjects received at least one dose of
Treatment Period 1
7–9 days





Platelet assessments and pharmacokinetic samples were assessed at Visit 2 (Day 1), Visit 3 (Day 7) and
Visit 4 (Day 8) in Treatment Period 1 and Visit 5 (Day 1), Visit 6 (Day 7) and Visit 7 (Day 8) in Treatment Period 2
Screening Visit 1
Platelet tests Platelet tests









180 mg/90 mg BID
Platelet tests Platelet tests
Platelet tests Platelet tests
Fig. 1 Study design. Hispanic subjects with CAD and treated with
aspirin therapy were randomly assigned in a 1:1 fashion to one of two
treatment sequences: either ticagrelor 180 mg LD and 90 mg twice-
daily MD for 7–9 days, followed by a washout period and clopidogrel
600 mg LD and 75 mg once-daily MD for 7–9 days, or clopidogrel
600 mg LD and 75 mg once-daily MD for 7–9 days, followed by a
washout period and ticagrelor 180 mg LD and 90 mg twice-daily MD
for 7–9 days. Platelet reactivity assessment and ticagrelor plasma
concentrations were measured at several timepoints around the LD
and at the end of the MD phase. CAD coronary artery disease, LD
loading dose, MD maintenance dose
Patients screened for 
eligibility (n = 53)
Criteria not met:
– No informed consent (n = 3)
– Oral anticoagulant (n = 2)
– Diabetic with HbA1c>10% 
(n = 4)
– Acute or chronic unstable 
condition (n = 1)
– Involved in planning/conduct of 
study (n = 1)
– ACS or stent (n = 1)
– AST, ALT, or total bilirubin 
>1.5xULN (n = 1)
Criteria met but not randomized:
– Withdrew due to other (n = 1)
Randomized 
(n = 40)
Allocated to treatment with 
clopidogrel: Period 1 (n = 20)
Completed clopidogrel (n = 20)
Allocated to treatment with 
ticagrelor: Period 1 (n = 20)
Completed ticagrelor (n = 19)
Cross over to ticagrelor: 
Period 2 (n = 20)
Completed ticagrelor   (n = 20)
Cross over to clopidogrel: 
Period 2 (n = 19)
Completed clopidogrel (n = 20)
Completed Study
(n = 38, 95%)
Fig. 2 Study flow. A total of 40 subjects were randomly assigned to a
treatment sequence, of which 39 completed at least one follow-up
visit and of which 38 completed at least 7 days of the maintenance
dosing phase for both study drugs
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clopidogrel. A total of 38 subjects completed the study.
Clinical characteristics and demographics of the random-
ised subjects are shown in Table 1. The mean age was
63.8 ± 8.8 years, 28 subjects (70 %) were male, 21 (53 %)
had diabetes mellitus, and 26 (65 %) had a prior myocar-
dial infarction. Data from three subjects with baseline on-
treatment reactivity \150 PRU were excluded from the
primary analysis, as this observation was felt to be con-
sistent with an incomplete washout from a P2Y12 antago-
nist and/or the presence of an interfering agent. These
values were included in a post hoc sensitivity analysis.
Pharmacodynamic effects of ticagrelor and clopidogrel
The antiplatelet effect of study drug LD is shown in
Table 2 and Fig. 3. At 2 h post-LD, the primary endpoint
of the study, on-treatment reactivity was significantly lower
after ticagrelor compared with clopidogrel (LS means dif-
ference, -167 PRU [95 % CI -197, -137], P \ 0.001).
This greater anti-platelet effect was evident within 30 min
after the LD and persisted at 8 h after the LD (Table 2).
The antiplatelet effects of ticagrelor 90 mg twice-daily MD
and clopidogrel 75 mg once-daily MD after 7–9 days of
dosing are shown in Table 3 and Fig. 3. On-treatment
reactivity was significantly lower with ticagrelor compared
with clopidogrel 2 h and 8 h after the MD, and was sig-
nificantly lower at the end of the dosing interval (12 h after
the last ticagrelor MD and 24 h after the last clopidogrel
MD). On sensitivity analysis, the primary results were
similar when data from the three subjects with abnormally
low baseline reactivity were included (LS means difference
at 2 h post-LD between ticagrelor and clopidogrel, –154.4
PRU [95 % CI -187.4, -121.4], P \ 0.001). The results
of other sensitivity analyses were also similar to the pri-
mary analysis (see Online Appendix.)
Pharmacokinetic profiles of ticagrelor and its
metabolite, AR-C124910XX
The pharmacokinetic (PK) profiles of ticagrelor and AR-
C124910XX during the LD and MD phases are shown in
Table 4. There was a rapid onset of circulating ticagrelor,
and the concentration was greatest at the 2-hour post-LD
measurement. After repeated dosing during the mainte-
nance phase of treatment, the mean ticagrelor plasma
concentration 2 h after a MD was generally consistent with
that at 2 h after the LD.
Adverse events
There were no serious adverse events, bleeding events, or
other adverse events that led to discontinuation of study
medication.
Discussion
This is the first randomised, pharmacodynamic (PD) and
PK study to specifically compare the antiplatelet effect of
ticagrelor and clopidogrel in a pre-defined and statistically
powered population of Hispanic patients with stable CAD.
We demonstrate that among Hispanic subjects with stable
CAD on low-dose aspirin, a ticagrelor 180 mg LD has a
more rapid onset of effect compared with clopidogrel
600 mg LD, and that within 30 min, ticagrelor reduced
platelet reactivity to a significantly greater extent than
clopidogrel, an effect that persisted during the maintenance
Table 1 Demographics and clinical characteristics of the study
population
Total (N = 40)
Age (years), mean ± SD 63.8 ± 8.8
Age C 65 (years), n (%) 18 (45)
Male sex, n (%) 28 (70)
Hypertension, n (%) 38 (95)
Dyslipidaemia, n (%) 39 (98)
Diabetes mellitus, n (%) 21 (53)
Body mass index, mean ± SD 30.2 ± 5.3
Heart failure, n (%) 3 (8)
Prior myocardial infarction, n (%) 26 (65)
Prior percutaneous coronary intervention, n (%) 32 (80)
SD standard deviation
Table 2 Comparative antiplatelet effect of ticagrelor 180 mg LD compared with clopidogrel 600 mg LD in Hispanic subjects with CAD
Timepoint Ticagrelor 180 mg LD Clopidogrel 600 mg LD LS means difference P value
Primary endpoint
2 h post-LD (95 % CI) 34 (12, 56) 201 (179, 224) -167 (-197, -137) \0.001
Secondary endpoints
0.5 h post-LD (95 % CI) 135 (105, 164) 270 (239, 301) -135 (-172, -98.0) \0.001
8 h post-LD (95 % CI) 34 (9, 59) 203 (177, 229) -169 (-204, -134) \0.001
All measurements are in PRU
CAD coronary artery disease, CI confidence interval, LD loading dose, LS least squares, PRU P2Y12 reaction unit
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phase of treatment. The PK of ticagrelor and its metabolite
AR-C124910XX were consistent with these findings.
The antiplatelet onset of ticagrelor and its effect during
the maintenance phase compared with that of clopidogrel
was previously evaluated by Gurbel et al. [5], who reported
no subjects of Hispanic ethnicity. In that study, on-treat-
ment reactivity measured by PRU was significantly lower
in the ticagrelor group at all assessed times in the first 24 h
after loading and during the maintenance phase. In the
current study, the mean on-treatment reactivity with ti-
cagrelor 180 mg LD/90 mg twice-daily MD was signifi-
cantly lower than clopidogrel 600 mg LD/75 mg once-
daily MD at all measured times starting 30 min after the
loading dose. Specifically, the mean on-treatment reactivity
was 135 PRU lower 30 min after the LD, 167 PRU lower
2 h after the loading dose (P \ 0.001), and 131 PRU lower
at the time of the next scheduled maintenance dose; these
differences are similar to the VerifyNow P2Y12 test results
reported by Gurbel et al. [5]. Plasma concentrations of ti-
cagrelor and AR-C124910XX were also consistent with
those observed in previous studies of ticagrelor. Therefore,
although we did not directly compare the PD and PK of
ticagrelor in Hispanics with non-Hispanics, the antiplatelet
effect of ticagrelor among Hispanics appears to be con-
sistent with that observed among the non-Hispanics that
make up the bulk of subjects upon which the prior reported
experience is based.
Racial and ethnic disparities in cardiovascular care are
important public health issues. For example, Hispanic
patients have longer delays to reperfusion than non-His-
panic Whites [6]; non-Whites, including Hispanics, pre-
senting with ACS have worse prognosis [7]; and Mexican-
Americans are at higher risk of cardiovascular mortality at
younger ages than non-Hispanic Whites [8]. The disparity
in cardiovascular care also extends to the conduct of ran-
domised, clinical trials. In the PLATO study there was a
trend towards higher overall event rates among 1,237
patients with ACS included in Central/South America, as
compared to patients included in Asia/Australia, Europe/
Middle East/Africa or North America. However, the
overall results for primary efficacy and safety were con-
sistent in patients included in Central/South America [3].
The present study, which demonstrates a fast and consistent
effect on platelet aggregation, support the observation from
PLATO. PD studies such as the current one provide





































































Fig. 3 On-treatment platelet reactivity on ticagrelor and clopidogrel
in Hispanic subjects with CAD receiving low-dose aspirin. a On-
treatment reactivity at baseline and after a ticagrelor 180 mg LD or
clopidogrel 600 mg LD and after 7–9 days of MD therapy with
ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily.
b Percentage reduction from baseline in on-treatment reactivity after a
ticagrelor 180 mg LD or clopidogrel 600 mg LD and after 7–9 days
of MD with ticagrelor 90 mg twice daily or clopidogrel 75 mg once
daily. Values are expressed as the least square means and 95 %
confidence intervals. LD loading dose, MD maintenance dose.
***P \ 0.001
Table 3 Comparative antiplatelet effect of ticagrelor compared with clopidogrel maintenance dosing in Hispanic subjects with CAD
Timepoint Ticagrelor 180 mg LD Clopidogrel 600 mg LD LS means difference P value
End of dosing intervala (95 % CI) 52 (30, 73) 182 (160, 205) -131 (-158, -103) \0.001
2 h after dose (95 % CI) 29 (8, 49) 179 (158, 200) -151 (-177, -124) \0.001
8 h after dose (95 % CI) 39 (17, 60) 179 (157, 201) -140 (-168, -112) \0.001
All measurements are in PRU. Platelet reactivity was assessed at least 7 days of maintenance dosing (ticagrelor 90 mg twice daily and
clopidogrel 75 mg once daily)
CAD coronary artery disease, LD loading dose, LS least squares
a 12 h after last evening dose of ticagrelor and 24 h after the last morning dose of clopidogrel
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does not appear to differ among this ethnic subgroup. The
consistent observations with our PK analysis, which track
the PD profile, support these findings. Robust demographic
data collection in clinical practice combined with com-
parative effectiveness studies are required to fully explore
whether there are substantial differences in clinical efficacy
among population subsets. Further studies are also needed
to assess the PD effect and clinical efficacy of antiplatelet
agents within ethnicities that have a substantial burden of
CAD but are not well-represented in large, randomised,
clinical trials.
This study has several limitations. The present study was
not designed to examine the relation of clinical outcomes
and platelet function. Subjects were self-identified as His-
panic. This follows the policy of the United States Food
and Drug Administration for the collection of race and
ethnicity, as well as that of the United States Department of
Health and Human Services. We evaluated patients with
stable CAD, and the PD and PK of ticagrelor and clopi-
dogrel may differ among patients with ACS. Of note, the
subjects in this study were a higher-risk CAD cohort, as
two-thirds had a prior history of myocardial infarction,
80 % had prior percutaneous coronary intervention, 33 %
had prior coronary artery bypass grafting, and diabetes
mellitus was present in more than half. The Prevention of
Cardiovascular Events in Patients With Prior Heart Attack
Using Ticagrelor Compared to Placebo on a Background of
Aspirin (PEGASUS)-TIMI 54 trial (clinicaltrials.gov
identifier, NCT01225562) will examine the safety and
efficacy of ticagrelor in combination with low-dose aspirin
in patients with a prior myocardial infarction and an
additional risk factor, including diabetes mellitus or multi-
vessel disease; therefore, the findings of the current study
may provide insight into the anticipated PD and PK of the
ticagrelor 90 mg twice-daily MD being examined within
that trial.
Conclusion
Among Hispanic subjects with stable CAD, a ticagrelor
180 mg LD followed by 90 mg twice-daily MD provides a
more rapid onset of platelet inhibition and a significantly
greater antiplatelet effect compared with clopidogrel
600 mg LD followed by 75 mg once-daily MD during both
the loading and maintenance phases of treatment. The PK
profiles of ticagrelor and its metabolite AR-C124910XX
were consistent with these findings.
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